Literature DB >> 15209602

Suboptimal statin adherence and discontinuation in primary and secondary prevention populations.

Jeffrey J Ellis1, Steven R Erickson, James G Stevenson, Steven J Bernstein, Renee A Stiles, A Mark Fendrick.   

Abstract

OBJECTIVES: To compare statin nonadherence and discontinuation rates of primary and secondary prevention populations and to identify factors that may affect those suboptimal medication-taking behaviors.
DESIGN: Retrospective cohort utilizing pharmacy claims and administrative databases.
SETTING: A midwestern U.S. university-affiliated hospital and managed care organization (MCO). PATIENTS: Non-Medicaid MCO enrollees, 18 years old and older, who filled 2 or more statin prescriptions from January 1998 to November 2001; 2258 secondary and 2544 primary prevention patients were identified. MEASUREMENTS: Nonadherence was assessed by the percent of days without medication (gap) over days of active statin use, a measurement known as cumulative multiple refill-interval gap (CMG). Discontinuation was identified by cessation of statin refills prior to the end of available pharmacy claims data.
RESULTS: On average, the primary and secondary groups went without medication 20.4% and 21.5% of the time, respectively (P=.149). Primary prevention patients were more likely to discontinue statin therapy relative to the secondary prevention cohort (relative risk [RR], 1.24; 95% confidence interval [CI], 1.08 to 1.43). Several factors influenced nonadherence and discontinuation. Fifty percent of patients whose average monthly statin copayment was < US dollars 10 discontinued by the end of follow-up (3.9 years), whereas 50% of those who paid >US dollars 10 but <or=US dollars 20 and >US dollars 20 discontinued by 2.2 and 1.0 years, respectively (RR, 1.39 and 4.30 relative to <US dollars 10 copay, respectively).
CONCLUSIONS: Statin nonadherence and discontinuation was suboptimal and similar across prevention categories. Incremental efforts, including those that decrease out-of-pocket pharmaceutical expenditures, should focus on improving adherence in high-risk populations most likely to benefit from statin use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209602      PMCID: PMC1492382          DOI: 10.1111/j.1525-1497.2004.30516.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  26 in total

1.  Gauging the impact of statins using number needed to treat.

Authors:  C R Kumana; B M Cheung; I J Lauder
Journal:  JAMA       Date:  1999-11-24       Impact factor: 56.272

2.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

3.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

4.  Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey.

Authors:  Karin Nelson; Keith Norris; Carol M Mangione
Journal:  Arch Intern Med       Date:  2002-04-22

5.  Withdrawal of statins increases event rates in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Christian W Hamm; Ulrich Laufs; Steven Snapinn; Michael Böhm; Harvey D White
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

6.  A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost.

Authors:  A M Fendrick; D G Smith; M E Chernew; S N Shah
Journal:  Am J Manag Care       Date:  2001-09       Impact factor: 2.229

7.  Adherence with statin therapy in elderly patients with and without acute coronary syndromes.

Authors:  Cynthia A Jackevicius; Muhammad Mamdani; Jack V Tu
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

8.  Long-term persistence in use of statin therapy in elderly patients.

Authors:  Joshua S Benner; Robert J Glynn; Helen Mogun; Peter J Neumann; Milton C Weinstein; Jerry Avorn
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study.

Authors:  L Wei; J Wang; P Thompson; S Wong; A D Struthers; T M MacDonald
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

View more
  93 in total

Review 1.  Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review.

Authors:  Mary A De Vera; Vidula Bhole; Lindsay C Burns; Diane Lacaille
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

2.  The many C's of primary care.

Authors:  Kurt Kroenke
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

3.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

4.  Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.

Authors:  Anna Citarella; Marie Linder; Helle Kieler; Ingegärd Anveden Berglind; Anders Sundström; Björn Wettermark; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2015-12-16       Impact factor: 2.953

5.  Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Joseph Yeboah; Stefan Sillau; Joseph C Delaney; Michael J Blaha; Erin D Michos; Rebekah Young; Waqas T Qureshi; Robyn McClelland; Gregory L Burke; Bruce M Psaty; David M Herrington
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

6.  Challenges in making therapeutic lifestyle changes among hypercholesterolemic African-American patients and their physicians.

Authors:  Rhonda Dailey; Kendra L Schwartz; Juliann Binienda; Jessica Moorman; Anne Victoria Neale
Journal:  J Natl Med Assoc       Date:  2006-12       Impact factor: 1.798

7.  Generic vs brand originator alendronate: analysis of persistence and compliance in five Local Healthcare Units in the Lombardy Region of Italy.

Authors:  Giorgio L Colombo; Carlo Maurizio Montecucco
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

8.  Effects of the 2013 American College of Cardiology/American Heart Association guidelines on racial and ethnic disparities in statin treatment among diabetics.

Authors:  Gregory A Phelps; Yanru Qiao; Merrion G Buckley; Junling Wang; Minghui Sam Li; Soumitra S Bhuyan; Marie A Chisholm-Burns
Journal:  Res Social Adm Pharm       Date:  2019-07-25

9.  Adherence to preventive statin therapy according to socioeconomic position.

Authors:  Helle Wallach-Kildemoes; Morten Andersen; Finn Diderichsen; Theis Lange
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

10.  Medication Nonadherence After Lung Transplantation in Adult Recipients.

Authors:  Anthony W Castleberry; Muath Bishawi; Mathias Worni; Loretta Erhunmwunsee; Paul J Speicher; Asishana A Osho; Laurie D Snyder; Matthew G Hartwig
Journal:  Ann Thorac Surg       Date:  2016-09-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.